University of Washington Medical Center, Seattle (D.D., C.M.O., G.B.M., M.R., J.M.M., G.S.A.).
Tours University Hospital, France (T.B., M.A.).
Circulation. 2018 Jan 23;137(4):388-399. doi: 10.1161/CIRCULATIONAHA.117.030729.
Bioprostheses are prone to structural valve degeneration, resulting in limited long-term durability. A significant challenge when comparing the durability of different types of bioprostheses is the lack of a standardized terminology for the definition of a degenerated valve. This issue becomes especially important when we try to compare the degeneration rate of surgically inserted and transcatheter bioprosthetic valves. This document, by the VIVID (Valve-in-Valve International Data), proposes practical and standardized definitions of valve degeneration and provides recommendations for the timing of clinical and imaging follow-up assessments accordingly. Its goal is to improve the quality of research and clinical care for patients with deteriorated bioprostheses by providing objective and strict criteria that can be utilized in future clinical trials. We hope that the adoption of these criteria by both the cardiological and surgical communities will lead to improved comparability and interpretation of durability analyses.
生物假体容易发生结构性瓣膜退化,导致长期耐用性有限。在比较不同类型生物假体耐用性时,一个重大挑战是缺乏用于定义退化瓣膜的标准化术语。当我们试图比较经外科植入和经导管生物假体瓣膜的退化率时,这个问题变得尤为重要。这份由 VIVID(经导管瓣中瓣国际数据)提出的文件,提出了瓣膜退化的实用和标准化定义,并相应提供了临床和影像学随访评估时间的建议。其目的是通过提供可用于未来临床试验的客观严格标准,提高患有退化生物假体患者的研究和临床护理质量。我们希望心脏科和外科领域都采用这些标准,从而提高耐用性分析的可比性和解释性。
JACC Cardiovasc Interv. 2020-1-27
Methodist Debakey Cardiovasc J. 2017
Catheter Cardiovasc Interv. 2020-9-1
Semin Thorac Cardiovasc Surg. 2015
EuroIntervention. 2016-9-18
Ann Med Surg (Lond). 2025-5-30
Ann Thorac Surg Short Rep. 2024-12-16
Front Bioeng Biotechnol. 2025-5-29
Eur Heart J Imaging Methods Pract. 2025-5-14
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2025-3-25
Int J Cardiol Congenit Heart Dis. 2024-12-20